Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948111

August 20, 2025Open Access

Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Changes in tumor fraction are significant predictors of clinical benefit from immune checkpoint inhibitors.
The study highlights the importance of methylation in assessing treatment outcomes, supporting personalized therapies.
Data was collected from the RADIOHEAD study focused on patient samples passing specific quality control metrics.
Findings suggest that monitoring ctDNA could enhance treatment strategies for cancer patients using immune therapy.

Implication

Real-world study identifies tumor fraction changes predicting long-term outcomes with immune checkpoint inhibitors in patients, suggesting potential monitoring strategies.

Abstract

Strobe diagram showing inclusion and exclusion for patient samples from the RADIOHEAD study in which successful samples passed all QC metrics and delivered a TF result. Chemo, chemotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc777 https://doi.org/10.1158/2767-9764.29948111

View Full Paper

Ask AI

Bookmark

Share

Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers